| Autor: |
van Meerten, Tom, Rozemuller, Henk, Mackus, Wendy J.M., Parren, Paul W.H.I., van de Winkel, Jan G.J., Claessen, Marie-Jose, van Rijn, Rozemarijn S., Hagenbeek, Anton, Martens, Anton C.M., Ebeling, Saskia B. |
| Zdroj: |
Blood; November 2006, Vol. 108 Issue: 11 p5488-5488, 1p |
| Abstrakt: |
Adoptive transfer of T cells is frequently associated with unwanted side effects. In order to tackle these effects one could introduce a safety switch into the cells that permits their selective in vivoelimination. The human CD20 gene in combination with CD20 antibodies was recently proposed as a novel safety switch. In such a system, T cells may be genetically modified with a CD20-encoding vector prior to adoptive transfer. If necessary, CD20-transgenic cells can be eliminated in vivothrough administration of CD20 antibodies, such as the chimeric antibody rituximab (RTX) that is currently used to treat CD20+ lymphoma. RTX activates the complement system and recruits immune effector cells, resulting in rapid death of CD20+ cells. Recently, a novel human CD20 antibody, Humab 7D8, was shown to have superior activity over RTX. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
